Clinical Trial Update: A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TQB2450 plus chemotherapy followed by TQB2450 plus anlotinib versus tislelizumab plus chemotherapy followed by tislelizumab in first-lin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer - Non-squamous First-line

Drugs mentioned

• Anlotinib (anlotinib)
• Chemotherapy (chemotherapy)
• TQB2450
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Non-squamous Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN